Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis

Abstract

Previous studies exploring associations between statin use and risk of multiple myeloma (MM) showed inconsistent results. We searched for articles published in English in databases (PubMed, Web of Science, EMBASE, Medline, and Google Scholar) before October 2019. The multivariate odds ratio (OR)/relative risk (RR) and 95% confidence intervals (CI) were computed to explore associations between statin use and risk of MM. The study indicated that statin users showed significantly lower risks of MM with a random effects model (OR/RR = 0.77, 95% CI 0.63 to 0.95, I2 = 63.1%, p for Q test = 0.001). Subgroup analyses showed that statin users showed significantly lower risks of MM in Caucasian populations with a fixed effects model (OR/RR = 0.72, 95% CI 0.59 to 0.88, I2 = 43.5%, p for Q test = 0.060), whereas no significant association was shown between statin use and risks of MM in Asian populations with a random effects model. Additionally, Subgroup analyses showed that statin users showed significantly lower risks of MM in cohort studies with a fixed effects model (RR = 0.83, 95% CI 0.74 to 0.93, I2 = 0.0%, p for Q test = 0.429), whereas no significant association was shown between statin use and risks of MM in case-control studies with a random effects model. In conclusion, the present study indicated that statin use might be a protective factor for MM incidence. However, the relationship between statin use and MM risk requires repeated and large prospective studies to be verified.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet (London, England) 385(9983):2197–2208. https://doi.org/10.1016/s0140-6736(14)60493-1

    Article  Google Scholar 

  2. 2.

    Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719–734. https://doi.org/10.1002/ajh.24402

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Kehrer M, Koob S, Strauss A, Wirtz DC, Schmolders J (2017) Multiple myeloma - current status in diagnostic testing and therapy. Z Orthop Unfallchirurgie 155(5):575–586. https://doi.org/10.1055/s-0043-110224

    Article  Google Scholar 

  4. 4.

    Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43(6):676–681. https://doi.org/10.1053/j.seminoncol.2016.11.004

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, Patel AV, Adami HO, Weiderpass E, Giles GG, Singh PN, Alavanja M, Beane Freeman LE, Bernstein L, Buring JE, Colditz GA, Fraser GE, Gapstur SM, Gaziano JM, Giovannucci E, Hofmann JN, Linet MS, Neta G, Park Y, Peters U, Rosenberg PS, Schairer C, Sesso HD, Stampfer MJ, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, de Gonzalez AB, Purdue MP (2014) Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol 166(5):667–676. https://doi.org/10.1111/bjh.12935

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61. https://doi.org/10.1093/annonc/mdx096

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52(22):1769–1781. https://doi.org/10.1016/j.jacc.2008.08.039

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Osmak M (2012) Statins and cancer: current and future prospects. Cancer Lett 324(1):1–12. https://doi.org/10.1016/j.canlet.2012.04.011

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Vallianou NG, Kostantinou A, Kougias M, Kazazis C (2014) Statins and cancer. Anti Cancer Agents Med Chem 14(5):706–712

    CAS  Article  Google Scholar 

  10. 10.

    Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14(2):107–119

    CAS  Article  Google Scholar 

  11. 11.

    Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15(10):e461–e468. https://doi.org/10.1016/s1470-2045(14)70119-6

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Huang BZ, Chang JI, Li E, Xiang AH, Wu BU (2017) Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J Natl Cancer Inst 109(5):djw275

    Article  Google Scholar 

  13. 13.

    Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY (2011) Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 106(12):2098–2103. https://doi.org/10.1038/ajg.2011.277

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15(5):921–925. https://doi.org/10.1158/1055-9965.epi-05-0866

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27–36. https://doi.org/10.1002/pds.1507

    Article  PubMed  Google Scholar 

  16. 16.

    Pradelli D, Soranna D, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G (2015) Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. Cancer Med 4(5):770–780. https://doi.org/10.1002/cam4.411

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clin Res Ed) 339:b2535. https://doi.org/10.1136/bmj.b2535

    Article  Google Scholar 

  18. 18.

    Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC (2017) Statin use and risk of multiple myeloma: an analysis from the cancer research network. Int J Cancer 141(3):480–487. https://doi.org/10.1002/ijc.30745

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71(5):1763–1771. https://doi.org/10.1158/0008-5472.can-10-2953

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, Kanda Y, Mori S, Suzuki R, Tachibana S, Yamane M, Odawara M, Mutou Y, Kami M (2006) Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97(2):133–138. https://doi.org/10.1111/j.1349-7006.2006.00153.x

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B (2016) Risk of multiple myeloma in a case-spouse study. Leuk Lymphoma 57(6):1450–1459. https://doi.org/10.3109/10428194.2015.1094693

    Article  PubMed  Google Scholar 

  22. 22.

    Chiu BCH, Chen JH, Yen YC, Calip GS, Chien CR, Ahsan H, Shih YCT, Cheng KF (2015) Long term statin use and risk of multiple myeloma among 15.5 million Taiwanese adults: a retrospective cohort study. Blood 126(23):4198

    Article  Google Scholar 

  23. 23.

    Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15(12):2342–2347. https://doi.org/10.1158/1055-9965.epi-06-0097

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Trojan PJ, Bohatch-Junior MS, Otuki MF, Souza-Fonseca-Guimaraes F, Svidnicki PV, Nogaroto V, Fernandes D, Krum EA, Favero GM (2016) Pravastatin induces cell cycle arrest and decreased production of VEGF and bFGF in multiple myeloma cell line. Braz J Biol 76(1):59–65. https://doi.org/10.1590/1519-6984.11914

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Slawinska-Brych A, Zdzisinska B, Mizerska-Dudka M, Kandefer-Szerszen M (2013) Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition. Leuk Res 37(5):586–594. https://doi.org/10.1016/j.leukres.2013.01.022

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58(23):5294–5297

    CAS  PubMed  Google Scholar 

  27. 27.

    Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G (2004) The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104(6):1825–1832. https://doi.org/10.1182/blood-2003-12-4218

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY (2011) Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol 670(2–3):356–364. https://doi.org/10.1016/j.ejphar.2011.09.031

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S (2007) Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 109(10):4415–4423. https://doi.org/10.1182/blood-2006-09-047076

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study received no funding.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pengcheng Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOC 63 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, P., Liu, B. Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis. Ann Hematol 99, 1805–1812 (2020). https://doi.org/10.1007/s00277-020-04157-5

Download citation

Keywords

  • Multiple myeloma
  • Statin
  • Meta-analysis